Will transdiagnostic focus on anhedonia reap rewards?

Anhedonia is common in schizophrenia as well as major depressive disorder, but it is complex, subtly different between indications, and difficult to study objectively. That is the rationale behind a new research consortium which aims to develop a panel of tasks to cast light on abnormalities in reward-related behavior across therapy areas.

The strength with which someone squeezes a handgrip may seem like a trivial task, but it is one that seems sensitive to differences between patients and healthy controls as a measure of how well they match effort to reward.2

When the reward for gripping the device hard (90% of maximum strength) was only ten cents per trial, more patients than healthy controls chose a hard grip. But when the reward was 40 cents, the reverse was true: fewer patients than controls chose to grip the device hard.1

Difficulties in relating effort to size of reward may be a feature of schizophrenia

Although both patients and controls were more likely to grip the device hard when the reward for doing so increased, the relationship between effort and reward was less strong among people with MDD and schizophrenia than among participants with no mental health problem.1


Behavioral differences implicate different neurotransmitters

This potentially revealing result – which replicates an earlier finding in people with schizophrenia1 -- comes from a collaborative study carried out by researchers at the Universities of Maastricht, Thessaloniki, Frankfurt-am-Main and Barcelona as part of the Reward Task Optimisation Consortium (RTOC). 

Abnormal reward processing could be a target in drug development

"Relative lack of flexibility on the Grip Effort Task may span MDD and schizophrenia, but there are probably also subtle differences between disorders in reward processing and the experience of pleasure, and these may relate to different neurotransmitter systems", Gerald Dawson (of RTOC) told an EPA 2021 Ask the Expert Session.

"One suggestion is that in MDD the primary deficit is in the strength of hedonic experience itself – related to altered GABA and opiate function – while in schizophrenia the main problem lies in impaired reward or goal representation, implicating altered dopamine function", Dr Dawson said.

Subtle differences may reflect deficits in GABA or opiate or dopamine systems


Mania may reflect lack of sensitivity to loss

The Consortium is also investigating a working memory and reinforcement task which requires subjects to learn the relationship between different shapes and levels of reward. Functional MRI has been used to show how prefrontal cortex working memory interacts with the dopaminergic reinforcement learning system when rewards received differ from those that subjects predicted.2

"The wider hope is that reward processing tasks will provide standardized, objective and quantifiable measures of anhedonia and impaired motivation. These can then be used in clinical trials of drugs in development for depression and schizophrenia but also, for example, bipolar disorder where – in the manic phase – the problem may be a relative lack of sensitivity to loss", Dr Dawson suggested.


MDD: Major Depressive Disorder
RTOC:  the Reward Task Optimisation Consortium
EPA: European Psychiatric Association
GABA: Gamma-Aminobutyric acid

BE-NOTPR-0078, approval date 09/2021

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.


1. Reddy LF et al. Schizophr Bull 2015; 41: 1045-1054

2. Collins AGE et al. J Neuroscience 2017; 37: 4332-4342

You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intended for health care professionals.
All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country